Provectus Biopharmaceuticals, Inc. (OTCMKTS:PVCT) Short Interest Down 65.9% in January

Provectus Biopharmaceuticals, Inc. (OTCMKTS:PVCT) was the recipient of a large drop in short interest in the month of January. As of January 15th, there was short interest totalling 2,900 shares, a drop of 65.9% from the December 31st total of 8,500 shares. Based on an average daily volume of 300,500 shares, the short-interest ratio is currently 0.0 days.

Provectus Biopharmaceuticals Price Performance

PVCT traded down $0.00 during mid-day trading on Wednesday, hitting $0.11. 7,000 shares of the stock were exchanged, compared to its average volume of 201,244. The firm’s fifty day moving average is $0.12 and its two-hundred day moving average is $0.11. Provectus Biopharmaceuticals has a 1-year low of $0.04 and a 1-year high of $0.22.

Provectus Biopharmaceuticals Company Profile

Provectus Biopharmaceuticals, Inc, a clinical-stage biotechnology company, engages in developing immunotherapy medicines based on halogenated xanthenes in the United States. The company's lead molecule is rose bengal sodium (RBS). Its clinical development programs include PV-10 for the treatment of stage III and IV melanoma and different types of liver cancers; PH-10 for the treatment of psoriasis and atopic dermatitis, and skin inflammation; and PV-305 for the treatment of infectious keratitis.